Patient-Reported Outcomes In Patients With Primary Advanced Or Recurrent Endometrial Cancer Treated With Chemotherapy Plus Dostarlimab Or Placebo In The ENGOT-EN6-NSGO/GOG3031/RUBY Trial Over 3 Years Of Follow-Up

Sharma S., Lindahl G., Landrum L. M., Pishchyk M., Gilbert L., Gill S., ...Daha Fazla

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, sa.2, 2025 (SCI-Expanded, Scopus)